OBJECTIVES: Evaluating the burden of a disease is a new way of measuring its impact on the lives of sufferers, as it takes into account all the problems caused by the illness. The ABC-V questionnaire was created and published in 2010 (Phlebology, 2010-25 :280-285). METHODS: It was administered to a population under treatment with phlebotonic drugs (Ruscus aculeatus, Hespéridine méthyl chalcone, ascorbic acid) RESULTS: Sixty-five subjects were monitored for 56 days, average age 47±16.7, gender: 60% women, with an average BMI of 24.76±3,95.  At inclusion and before treatment, the burden score was 32.8±17.6. No difference was observed according to gender (the male score was 33.6 ±20.2, the female 32.3±15.48 p=0.4) , to age (35.2 ± 12.4 in those older than 55 vs  31.15±20.2 in the younger age braced (p=0.2); There was a difference, however, in the ABC-V score dependent on sport activity: 36.05  vs 27,68(p<0.02)  On days 28 and 56, the burden score was 22.6±13.9 and 19.6±13.8 respectively. The burden is therefore observed to have significantly and statistically reduced. The quantity of effect has been measured, and the burden is 27% reduced on the day  28 and 40% on day 56. Aside from averages, a reduction in burden was observed in nearly 93% of subjects. For 68% of subjects the reduction was greater than 30% by the 56th day. Greater reduction of burden was observed in  subjects who took regular exercise, vs those who did not (41% vs 38%) and under 50 vs over 50 (47% vs 31%) The scores that improved the most were: treatment by GP (58%) , daily life (52%) and psychological impact (54%) CONCLUSIONS: The ABC-V burden questionnaire was created and validated in 2010 (psychometric and cognitive debriefing). This study has demonstrated and confirmed its sensitivity to change. It is available in French, English, Italian and Spanish.